<DOC>
	<DOCNO>NCT02073682</DOCNO>
	<brief_summary>Edoxaban similar dalteparin prevent recurrence acute VTE follow initial index event cancer subject .</brief_summary>
	<brief_title>Cancer Venous Thromboembolism ( VTE )</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Male female subject age â‰¥ 18 year otherwise legal low age accord country residence ; Confirmed acute low extremity proximal DVT PE long term treatment low molecular weight heparin ( LMWH ) indicate ; Cancer , basalcell squamouscell carcinoma skin ; Able provide write informed consent . Thrombectomy , insertion caval filter , use fibrinolytic agent treat current ( index ) episode DVT and/or PE ; Treatment therapeutic dos anticoagulant use pretreatment current ( index ) VTE episode prior randomization ; Active bleeding high risk bleed contraindicate treatment LMWH edoxaban ; Any contraindication list local labeling dalteparin , enoxaparin , edoxaban ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>